Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hainan Huluwa Pharmaceutical Group Co's quarterly market cap
declined
from Sep. 2025 (¥3,533.0 Mil) to Dec. 2025 (¥3,048.8 Mil) and
declined
from Dec. 2025 (¥3,048.8 Mil) to Mar. 2026 (¥2,732.7 Mil).
Hainan Huluwa Pharmaceutical Group Co's annual market cap
increased
from Dec. 2023 (¥6,065.7 Mil) to Dec. 2024 (¥6,373.7 Mil) but then
declined
from Dec. 2024 (¥6,373.7 Mil) to Dec. 2025 (¥3,048.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Hainan Huluwa Pharmaceutical Group Co's Enterprise Value for Today is ¥3,310.3 Mil.
Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Hainan Huluwa Pharmaceutical Group Co Market Cap Related Terms
Hainan Huluwa Pharmaceutical Group Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hainan Huluwa Pharmaceutical Group Co Market Cap Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Hainan Huluwa Pharmaceutical Group Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hainan Huluwa Pharmaceutical Group Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hainan Huluwa Pharmaceutical Group Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Hainan Huluwa Pharmaceutical Group Co's Market Cap falls into.
Hainan Huluwa Pharmaceutical Group Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) has a Market Cap of ¥2,192.6 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hainan Huluwa Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Hainan Huluwa Pharmaceutical Group Co ranks #453 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 44.3%.
Is Hainan Huluwa Pharmaceutical Group Co's Market Cap too high?
Hainan Huluwa Pharmaceutical Group Co's current Market Cap is ¥2,192.6 Mil. Based on the distribution chart, Hainan Huluwa Pharmaceutical Group Co ranks #453 out of 1022 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hainan Huluwa Pharmaceutical Group Co has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hainan Huluwa Pharmaceutical Group Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hainan Huluwa Pharmaceutical Group Co ranks #453 out of 1022 companies for Market Cap. This puts Hainan Huluwa Pharmaceutical Group Co in the upper half of its industry. The industry median Market Cap is 220.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 220.60, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hainan Huluwa Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 220.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hainan Huluwa Pharmaceutical Group Co's current Market Cap is ¥2,192.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hainan Huluwa Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.85, compared to a current price of ¥5.48 — trading 6.3% below its estimated fair value. The current Market Cap is ¥2,192.6 Mil. Hainan Huluwa Pharmaceutical Group Co's overall GF Score™ is 50/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Hainan Huluwa Pharmaceutical Group Co (SHSE:605199), the current Market Cap is ¥2,192.6 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Overvalued in 2026?
Based on GuruFocus' analysis, Hainan Huluwa Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥5.48 is trading 6.3% below its estimated GF Value™ of ¥5.85.
GuruFocus considers Hainan Huluwa Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:605199:
Market Cap: ¥2,192.6 Mil
GF Value™: ¥5.85 vs. price of ¥5.48 (6.3% below fair value)
No single metric tells the full story. See the SHSE:605199 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hainan Huluwa Pharmaceutical Group Co Business Description
Hainan Huluwa Pharmaceutical Group Co Ltd is engaged in production and sales of Chinese patent medicines and chemical drugs. The company produces medicines for children's respiratory and digestive systems. Its products include star products, calabash, gourd dad, and gourd mom.
50GF Score
Get the complete analysis for SHSE:605199
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605199 has been successfully added to your 
